8582results about "Carbonyl compound preparation" patented technology

A reactive-separation process converts glycerin into lower alcohols, having boiling points less than 200° C., at high yields. Conversion of natural glycerin to propylene glycol through an acetol intermediate is achieved at temperatures from 150° to 250° C. at a pressure ranging from 1 and 25 bar. The preferred applications of the propylene glycol are as an antifreeze, deicing compound, or anti-icing compound. The preferred catalyst for this process in a copper-chromium powder.

The present invention relates to non-secosteroidal compounds which activate and modulate the vitamin D receptor (VDR). Because compounds of the present invention display many of the beneficial properties of 1,25(OH)2D3, but with reduced calcium mobilization effects, they may be used advantageously to treat and prevent conditions that show vitamin D sensitivity. Such disease states typically show abnormal calcium regulatory, abnormal immune responsive, hyperproliferative, and/or neurodegenerative characteristics.

Carbon dioxide is used as a reaction solvent in the hydrogenation of organic compounds. The carbon dioxide is preferably a liquid or a supercritical fluid. The hydrogenation method can be used advantageously in methods for making tetrahydroiso-alpha-acids from alpha-acids, iso-alpha-acids, or beta-acids. If beta-acids are used to make tetrahydroiso-alpha-acids, an acidic lower alcohol is preferably added to the carbon dioxide reaction medium to act as a promoter.

The invention relates to a process for producing high-quality hydrocarbon base oil particularly of biological origin. The process of the invention comprises aldol condensation, hydrodeoxygenation, and isomerization steps. Aldehydes and/or ketones, preferably of biological origin are used as the feedstock.

A drug may be used in the preparation of a medicament for the treatment or prevention of an ophthalmologic disorder, wherein the drug inihibits, antagonizes, or short-circuits the visual cycle at a step of the visual cycle that occurs outside a disc of a rod photoreceptor cell.

The present invention provides modified cycloalkyne compounds; and method of use of such compounds in modifying biomolecules. The present invention features a cycloaddition reaction that can be carried out under physiological conditions. In general, the invention involves reacting a modified cycloalkyne with an azide moiety on a target biomolecule, generating a covalently modified biomolecule. The selectivity of the reaction and its compatibility with aqueous environments provide for its application in vivo (e.g., on the cell surface or intracellularly) and in vitro (e.g., synthesis of peptides and other polymers, production of modified (e.g., labeled) amino acids).

The present invention provides modified cycloalkyne compounds; and method of use of such compounds in modifying biomolecules. The present invention features a cycloaddition reaction that can be carried out under physiological conditions. In general, the invention involves reacting a modified cycloalkyne with an azide moiety on a target biomolecule, generating a covalently modified biomolecule. The selectivity of the reaction and its compatibility with aqueous environments provide for its application in vivo (e.g., on the cell surface or intracellularly) and in vitro (e.g., synthesis of peptides and other polymers, production of modified (e.g., labeled) amino acids).

One aspect of the present invention relates to novel ligands for transition metals. A second aspect of the present invention relates to the use of catalysts comprising these ligands in transition metal-catalyzed carbon-heteroatom and carbon-carbon bond-forming reactions. The subject methods provide improvements in many features of the transition metal-catalyzed reactions, including the range of suitable substrates, reaction conditions, and efficiency.

The present invention relates to Diphenylethylene Compounds and compositions comprising a Diphenylethylene Compound. The present invention also relates to methods for preventing or treating various diseases and disorders by administering to a subject in need thereof one or more Diphenylethylene Compounds. In particular, the invention relates to methods for preventing or treating cancer or an inflammatory disorder by administering to a subject in need thereof one or more Diphenylethylene Compounds. The present invention further relates to articles of manufacture and kits comprising one or more Diphenylethylene Compounds.

The invention relates to a synthesis method of D,L-danshensu isopropyl ester. The method comprises taking protocatechuic aldehyde as an initial raw material, protecting phenolic hydroxyl by benzyl, carrying out Darzens epoxidation, followed by carrying out catalytic reduction with palladium catalyst/hydrogen or Raney nickel/hydrogen, and thus obtaining the D,L-danshensu isopropyl ester. The purity of the product synthesized by the method can reach 98%, and the yield can reach 55%. Moreover, the synthesis method has the advantages of simple and easily obtained raw materials, short routes and high yield, and is suitable for large-scale industrialized production.

The invention relates to a synthesis method of racemic bornyl beta-(3,4-dihydroxyphenyl)-alpha-hydroxypropionate. The method comprises the following steps: carrying out Darzens epoxidation on an initial raw material benzyl protected protocatechualdehyde, and carrying out palladium catalyst/hydrogen or Raney nickel/hydrogen catalytic reduction to obtain racemic bornyl beta-(3,4-dihydroxyphenyl)-alpha-hydroxypropionate. The purity and the yield of a product synthesized by adopting the method reach 98% and 48.6% respectively. The synthesis method has the advantages of simple and easily available raw material, short route, high yield, and suitableness for large scale industrialized production.

Provided is an organic metal complex having a structure represented by the following general formula (1):

ML_mL′_n  (1)

where: M represents a metal atom selected from Ir, Pt, Rh, Os, and Zn; L and L′, which are different from each other, each represent a bidentate ligand; m represents an integer of 1 to 3 and n represents an integer of 0 to 2, provided that m+n is 3; a partial structure ML_m represents a structure represented by the following general formula (2):

and a partial structure ML′_n represents a structure including a monovalent bidentate ligand.

There is disclosed a production process for a catalyst which process makes it possible to efficiently carry out the supporting of a catalytic component onto a carrier and to obtain the catalyst excellent in quality and performance. This production process is a production process for the catalyst including a particulate lump carrier and a catalytic component supported thereon; with the production process comprising the step of carrying out simultaneous revolution and rocking of a treatment container 20 as charged with the carrier and a catalyst precursor including the catalytic component, thereby supporting the catalytic component onto the carrier.

The present invention generally relates to compositions comprising and methods for forming functionalized carbon-based nanostructures.

Cytoprotective compounds, many of which are phenolic derivatives characterized by a substituted phenol having certain conjugated bonds, are useful in the treatment of certain ischemic or inflammatory conditions, including but not limited to stroke, myocardial infarction, congestive heart failure, and skin disorders characterized by inflammation or oxidative damage. They are also useful in the manufacture of pharmaceutical and cosmetic formulations for the treatment of such conditions.

Reactor membranes for used in oxidation reactions of hydrocarbons involving oxygen comprising a selective oxidation catalyst on a mixed conducting, oxide ion selective ceramic membrane of the composition (Sr1-xCax)1-yAyMn1-zBzO3-delta, whereA is Ba, Pb, Na, K, Y, an element of the lanthanide group or a combination thereof,B is Mg, Al, Ga, In, Sn, an element of the 3d or 4d period or a combination thereof,x is from 0.2 to 0.8,y is from 0 to 0.4,z is from 0 to 0.6, anddelta is a number, dependent on x, y and z, that renders the composition charge neutral.

Methods are disclosed which utilize metabolites of bupropion for treating sexual dysfunction.

The present invention relates to a method of functionalizing a carbon material. A carbon material is contacted with a carboxylic acid, whereby a mixture is formed. The mixture is heated for a suitable period of time at a temperature below the thermal decomposition temperature of the carbon material.

A catalyst for producing from an olefin the corresponding unsaturated aldehyde and unsaturated carboxylic acid in high yield; and a process for producing the catalyst. The process is for producing a composite oxide catalyst which is for use in catalytically oxidizing an olefin in a vapor phase with a gas containing molecular oxygen to produce the corresponding unsaturated aldehyde and corresponding unsaturated carboxylic acid, and which comprises (A) molybdenum, (B) bismuth, (C) cobalt and/or nickel, and (D) iron. It is characterized in that catalyst precursor particles produced through a preceding step in which an aqueous dispersion containing a raw material for the ingredient (A), raw material for the ingredient (C), and raw material for the ingredient (D) which have been united with one another and having a nitric acid radical content satisfying the relationship 1.2<=NO3/(3xFe+2x(Co+Ni)) is dried and then heated are united with a raw material for the ingredient (B) in a water-miscible solvent and the resultant united matter is dried and burned. In the relationship, NO3, Fe, Co, and Ni indicate the molar contents of nitric acid radicals, iron, cobalt, and nickel, respectively.